Zeta IHC antibodies
Our immunohistochemistry (IHC) antibody portfolio now includes precision-engineered recombinant antibodies from Zeta Corporation, a leading U.S.-based manufacturer of IVD-grade reagents. Originally developed for clinical diagnostics, these antibodies are now available from Benchmark Antibodies for research use only (RUO)-bringing diagnostic-level quality and consistency to your research.
Zeta's proprietary recombinant platforms-MonoMAb™ and RAbMono™-deliver highly specific and reproducible results across a wide spectrum of tumor and tissue biomarkers. Designed to meet stringent ISO 13485:2016 standards, these antibodies ensure unmatched performance for researchers working with FFPE tissues in cancer biology, pathology, and biomarker discovery.
Key attributes of Zeta IHC Antibodies supplied by Benchmark Antibodies:
- IVD-Grade Quality: Developed under ISO-certified, FDA-registered conditions to ensure exceptional reliability and batch-to-batch consistency.
- High Specificity & Sensitivity: Engineered through high-throughput screening and recombinant sequencing for targeted performance on FFPE sections.
- Recombinant Technology: MonoMAb™ (mouse) and RAbMono™ (rabbit) antibodies provide superior reproducibility and supply security.
- Optimized for IHC: Each antibody is individually validated on formalin-fixed, paraffin-embedded tissues so ideal for research.
- Made in the USA: Manufactured domestically for consistent availability and supply chain confidence.
- Affordable Excellence: Competitive pricing provides research labs access to clinical-grade quality without clinical-grade costs.
- Technical Support: North American-based supplier providing knowledgeable, responsive customer support.
